Product logins

Find logins to all Clarivate products below.


Graft Versus Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2020

Graft versus host disease (GVHD) is a potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation (HSCT). GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue as foreign. For decades, steroids have been the first-line therapy for the prevention and treatment of GVHD, but interviewed experts call for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for GVHD. Although development in this space has historically been slow, the pipeline for GVHD therapies is now robust with a number of late-phase agents, including Mesoblast’s Ryoncil (remestemcel-L), Incyte’s itacitinib, Kadmon’s belumosudil, Elsalys / Mediolanum’s Leukotac (inolimomab), and Xenikos’s T-Guard. Here, we examine the clinical and commercial opportunity of these emerging therapies and how they may affect the commercial performance of current therapies, such as AbbVie / Janssen’s Imbruvica and Incyte / Novartis’s Jakafi / Jakavi.

QUESTIONS ANSWERED

  • How large is the GVHD population, and how will it change through 2029? What percentage of the GVHD population receives drug treatment?
  • How is GVHD currently managed in the United States and EU5? How well does the GVHD pipeline align with unmet needs in the space?
  • Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of GVHD? Which emerging drugs hold the most commercial potential?
  • What are some of the key GVHD market drivers and constraints? How will continuing advances in patient and host human leukocyte antigen (HLA) matching affect the market?

CONTENT HIGHLIGHTS

  • Geographies: United States and EU5.
  • Primary research: Six country-specific interviews with thought-leading GVHD specialists, supported by survey data collected for this study.
  • Epidemiology: Diagnosed incident cases of acute and chronic GVHD, diagnosed incident cases of acute GVHD by grade, drug-treated cases of GVHD by country.
  • Forecast: Drug-level sales and patient share of key GVHD therapies in 2029.
  • Emerging therapies: Late phase / preregistered: 6 drugs; Phase II: >10 drugs; coverage of select preclinical and Phase I products.

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…